Chen Hsin Hsu, Kuo Ho Chang, Wang Ling, Yu Hong Ren, Shen Jiun Min, Kwang Kao Pin, Yang Kuender D
Division of Pediatric Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University, Kaohsiung, Taiwan.
J Microbiol Immunol Infect. 2007 Jun;40(3):265-71.
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome composed of macrophage activation syndrome (MAS), infection-associated hemophagocytosis syndrome (IAHS), malignancy-associated HLH and genetic HLH. Differentiation of MAS from IAHS and other HLH is important for early appropriate treatment.
A retrospective analysis was used to differentiate childhood MAS from IAHS and other HLH in Chang Gung Memorial Hospital (CGMH), Kaohsiung. All relevant clinical features, laboratory data, treatments and outcomes were analysed.
Seventeen patients with childhood HLH were found at CGMH, Kaohsiung in the past decade, and could be classified into 3 categories: IAHS (9 patients), MAS (5 patients), and HLH of unknown etiology (3 patients). The diagnosis of MAS first appeared in this hospital in 2001. Patients with IAHS tended to be younger than those with MAS. Boys were more frequently found in the IAHS group whereas girls (with systemic lupus erythematosus or juvenile idiopathic arthritis) were more frequently found in the MAS group. The majority of mortality cases were noted in the IAHS group (44%, 4/9). All patients with MAS survived with early cyclosporine A treatment.
Childhood MAS is different from IAHS in terms of age, gender, etiology and mortality. Early administration of cyclosporine A for MAS results in a lower mortality. Further prospective studies are required to confirm these findings.
噬血细胞性淋巴组织细胞增生症(HLH)是一种由巨噬细胞活化综合征(MAS)、感染相关噬血细胞综合征(IAHS)、恶性肿瘤相关HLH和遗传性HLH组成的综合征。区分MAS与IAHS及其他HLH对于早期进行恰当治疗很重要。
采用回顾性分析来区分高雄长庚纪念医院(CGMH)儿童MAS与IAHS及其他HLH。分析了所有相关临床特征、实验室数据、治疗方法及结果。
在过去十年中,高雄长庚纪念医院发现了17例儿童HLH患者,可分为3类:IAHS(9例)、MAS(5例)和病因不明的HLH(3例)。MAS的诊断于2001年首次出现在本院。IAHS患者往往比MAS患者年龄小。IAHS组男孩更常见,而MAS组女孩(患有系统性红斑狼疮或幼年特发性关节炎)更常见。大多数死亡病例出现在IAHS组(44%,4/9)。所有MAS患者经早期环孢素A治疗后存活。
儿童MAS在年龄、性别、病因和死亡率方面与IAHS不同。早期给予MAS环孢素A可降低死亡率。需要进一步的前瞻性研究来证实这些发现。